 |
PDBsum entry 1c5u
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Structural basis for selectivity of a small molecule, s1-binding, sub- micromolar inhibitor of urokinase type plasminogen activator
|
|
Structure:
|
 |
Protein (trypsin). Chain: a. Ec: 3.4.21.4
|
|
Source:
|
 |
Bos taurus. Cattle. Organism_taxid: 9913
|
|
Resolution:
|
 |
|
1.37Å
|
R-factor:
|
0.181
|
R-free:
|
0.195
|
|
|
Authors:
|
 |
B.A.Katz,R.Mackman,C.Luong,K.Radika,A.Martelli,P.A.Sprengeler,J.Wang, H.Chan,L.Wong
|
Key ref:
|
 |
B.A.Katz
et al.
(2000).
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
Chem Biol,
7,
299-312.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
22-Dec-99
|
Release date:
|
22-Dec-00
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P00760
(TRY1_BOVIN) -
Serine protease 1 from Bos taurus
|
|
|
|
Seq: Struc:
|
 |
 |
 |
246 a.a.
223 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.4.21.4
- trypsin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Preferential cleavage: Arg-|-Xaa, Lys-|-Xaa.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Chem Biol
7:299-312
(2000)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
|
|
B.A.Katz,
R.Mackman,
C.Luong,
K.Radika,
A.Martelli,
P.A.Sprengeler,
J.Wang,
H.Chan,
L.Wong.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
BACKGROUND: Urokinase-type plasminogen activator (uPA) is a protease associated
with tumor metastasis and invasion. Inhibitors of uPA may have potential as
drugs for prostate, breast and other cancers. Therapeutically useful inhibitors
must be selective for uPA and not appreciably inhibit the related, and
structurally and functionally similar enzyme, tissue-type plasminogen activator
(tPA), involved in the vital blood-clotting cascade. RESULTS: We produced
mutagenically deglycosylated low molecular weight uPA and determined the crystal
structure of its complex with 4-iodobenzo[b]thiophene 2-carboxamidine (K(i) =
0.21 +/- 0.02 microM). To probe the structural determinants of the affinity and
selectivity of this inhibitor for uPA we also determined the structures of its
trypsin and thrombin complexes, of apo-trypsin, apo-thrombin and apo-factor Xa,
and of uPA, trypsin and thrombin bound by compounds that are less effective uPA
inhibitors, benzo[b]thiophene-2-carboxamidine,
thieno[2,3-b]-pyridine-2-carboxamidine and benzamidine. The K(i) values of each
inhibitor toward uPA, tPA, trypsin, tryptase, thrombin and factor Xa were
determined and compared. One selectivity determinant of the
benzo[b]thiophene-2-carboxamidines for uPA involves a hydrogen bond at the S1
site to Ogamma(Ser190) that is absent in the Ala190 proteases, tPA, thrombin and
factor Xa. Other subtle differences in the architecture of the S1 site also
influence inhibitor affinity and enzyme-bound structure. CONCLUSIONS: Subtle
structural differences in the S1 site of uPA compared with that of related
proteases, which result in part from the presence of a serine residue at
position 190, account for the selectivity of small thiophene-2-carboxamidines
for uPA, and afford a framework for structure-based design of small, potent,
selective uPA inhibitors.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3. (a) Structure of
uPA–thieno[2,3-b]pyridine-2-carboxamidine, pH 6.5, at 1.65
Å resolution, on the (2|F[o]|–|F[c]|), α[c] map. The
occupancies of conformation 1 (with green carbons) and 2 (light
green carbons) are 66% and 34%, respectively. In the trypsin
complex the corresponding occupancies are 54% and 46% at pH 5.5,
and 31% and 69% at pH 8.2. (b) Superposition of uPA– and
trypsin–thieno[2,3-b]pyridine-2-carboxamidine, pH 5.5. For
clarity only the first conformation of the bound inhibitors is
shown. In each complex the aromatic rings of the two bound
conformations of the inhibitors lie in the same plane as one
another (see Figure 4a). The two locations of the Hγ proton of
Ser195 for the trypsin complex are shown.
|
 |
Figure 4.
Figure 4. Structures and associated (2|F[o]|–|F[c]|),
α[c] maps for (a) apo-trypsin, pH 7.7; and (b) apo-thrombin, pH
7.5, 1.47 Å resolution. In (b), the long
water1–O[Trp215] distance (3.4 Å) is indicated in cyan.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Chem Biol
(2000,
7,
299-312)
copyright 2000.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
N.Okimoto,
N.Futatsugi,
H.Fuji,
A.Suenaga,
G.Morimoto,
R.Yanai,
Y.Ohno,
T.Narumi,
and
M.Taiji
(2009).
High-performance drug discovery: computational screening by combining docking and molecular dynamics simulations.
|
| |
PLoS Comput Biol,
5,
e1000528.
|
 |
|
|
|
|
 |
D.Jiao,
P.A.Golubkov,
T.A.Darden,
and
P.Ren
(2008).
Calculation of protein-ligand binding free energy by using a polarizable potential.
|
| |
Proc Natl Acad Sci U S A,
105,
6290-6295.
|
 |
|
|
|
|
 |
N.Singh,
and
J.M.Briggs
(2008).
Molecular dynamics simulations of Factor Xa: insight into conformational transition of its binding subsites.
|
| |
Biopolymers,
89,
1104-1113.
|
 |
|
|
|
|
 |
A.V.Iakhiaev,
A.Nalian,
K.Koenig,
and
S.Idell
(2007).
Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis.
|
| |
Thromb Res,
120,
715-725.
|
 |
|
|
|
|
 |
V.Ramensky,
A.Sobol,
N.Zaitseva,
A.Rubinov,
and
V.Zosimov
(2007).
A novel approach to local similarity of protein binding sites substantially improves computational drug design results.
|
| |
Proteins,
69,
349-357.
|
 |
|
|
|
|
 |
A.Fernández,
R.Scott,
and
R.S.Berry
(2006).
Packing defects as selectivity switches for drug-based protein inhibitors.
|
| |
Proc Natl Acad Sci U S A,
103,
323-328.
|
 |
|
|
|
|
 |
M.Zentgraf,
J.Fokkens,
and
C.A.Sotriffer
(2006).
Addressing protein flexibility and ligand selectivity by "in situ cross-docking".
|
| |
ChemMedChem,
1,
1355-1359.
|
 |
|
|
|
|
 |
A.Fernández
(2005).
Incomplete protein packing as a selectivity filter in drug design.
|
| |
Structure,
13,
1829-1836.
|
 |
|
|
|
|
 |
E.Atkins,
S.Zamora,
B.J.Candia,
A.Baca,
and
R.A.Orlando
(2005).
Development of a Mammalian suspension culture for expression of active recombinant human urokinase-type plasminogen activator.
|
| |
Cytotechnology,
49,
25-37.
|
 |
|
|
|
|
 |
J.Tang,
C.L.Yu,
S.R.Williams,
E.Springman,
D.Jeffery,
P.A.Sprengeler,
A.Estevez,
J.Sampang,
W.Shrader,
J.Spencer,
W.Young,
M.McGrath,
and
B.A.Katz
(2005).
Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein.
|
| |
J Biol Chem,
280,
41077-41089.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.Jin,
P.Pandey,
R.E.Babine,
J.C.Gorga,
K.J.Seidl,
E.Gelfand,
D.T.Weaver,
S.S.Abdel-Meguid,
and
J.E.Strickler
(2005).
Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions.
|
| |
J Biol Chem,
280,
4704-4712.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.R.Somoza,
J.D.Ho,
C.Luong,
M.Ghate,
P.A.Sprengeler,
K.Mortara,
W.D.Shrader,
D.Sperandio,
H.Chan,
M.E.McGrath,
and
B.A.Katz
(2003).
The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain.
|
| |
Structure,
11,
1123-1131.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
B.A.Katz,
P.A.Sprengeler,
C.Luong,
E.Verner,
K.Elrod,
M.Kirtley,
J.Janc,
J.R.Spencer,
J.G.Breitenbucher,
H.Hui,
D.McGee,
D.Allen,
A.Martelli,
and
R.L.Mackman
(2001).
Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
|
| |
Chem Biol,
8,
1107-1121.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |